SGLT1/2 inhibitor shows early promise in NASH - medwireNews

The SGLT1/2 inhibitor licogliflozin has reduced liver enzyme levels in people with nonalcoholic steatohepatitis in a phase 2 trial published in Nature Medicine.

medwireNews: The sodium-glucose cotransporter (SGLT)1/2 inhibitor licogliflozin has reduced liver enzyme levels in people with nonalcoholic steatohepatitis (NASH) in a phase 2 trial published in Natu… [+1556 chars]

full article...